Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
Conditions
Keywords
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer, Memorial Sloan Kettering Cancer Center, 25-338
Brief summary
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.
Interventions
OTHERImmunotherapy CARE Program
For participants assigned to the I CARE arm, CCNY staff will assist in monthly essential needs and side effects/symptom reporting navigation
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documentation of Disease o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR) * Prior Treatment o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR) * Age ≥ 18 (per EMR) * Not Pregnant and Not Nursing (per self-report) * At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report) * Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report) * Can speak English or Spanish (per self-report) * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team) * Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immune Checkpoint Inhibitors/ICI continuation | 6 months | Participant ICI appointment and treatment adherence will be documented through chart abstraction (research staff EMR review) at 6 months |
Countries
United States
Contacts
CONTACTFrancesca Gany, MD, MS
CONTACTNeil Shah, MBBS
PRINCIPAL_INVESTIGATORFrancesca Gany, MD, MS
Memorial Sloan Kettering Cancer Center
Outcome results
None listed